Tigatx
1 known investors
Tigatx develops engineered IgA antibodies designed to engage neutrophils as a cancer treatment approach. The company focuses on first-in-class immunotherapy for cancer patients.
Biotech
1 known investors
Tigatx develops engineered IgA antibodies designed to engage neutrophils as a cancer treatment approach. The company focuses on first-in-class immunotherapy for cancer patients.